Antiretroviral activity of pegylated interferon alfa-2a in patients co-infected with HIV/hepatitis C virus
作者： D. Aguilar Marucco , L. Veronese , D. Gonzalez de Requena , S. Bonora , A. Calcagno
DOI: 10.1093/JAC/DKL497
关键词:
摘要: Objectives: To evaluate the early anti-HIV activity of pegylated interferon (PEG-IFN) alfa-2a and ribavirin in HIV/hepatitis C virus (HCV) co-infected patients not receiving antiretroviral therapy. Patients methods: In 19 with baseline plasma HIV load (HIV-RNA) >1000 copies/mL treated PEG-IFN ribavirin, HIV-RNA T-cell subsets were measured at 2, 4 12 weeks after initiation anti-HCV Results: We observed a significant decrease (>1 log 10 copies/mL) through week treatment. The magnitude decline was associated HIV-RNA, CD4 count weight-adjusted dose. Conclusions: A observed. Such an effect warrants further clinical evaluation management patients.
oup.com
oxfordjournals.org
sci-hub.se 参考文章(10)
HOWARD E. GENDELMAN, LISA BACA, JIM A. TURPIN, D. CHESTER KALTER, BRIAN D. HANSEN, JAN M. ORENSTEIN, ROBERT M. FRIEDMAN, MONTE S. MELTZER, Restriction of HIV Replication in Infected T Cells and Monocytes by Interferon-α AIDS Research and Human Retroviruses. ,vol. 6, pp. 1045- 1049 ,(1990) , 10.1089/AID.1990.6.1045
Angelos Hatzakis, Panagiotis Gargalianos, Vassilis Kiosses, Marios Lazanas, Vana Sypsa, Cleo Anastassopoulou, Vassilios Vigklis, Helen Sambatakou, Chrisoula Botsi, Dimitris Paraskevis, Carlos Stalgis, Low-Dose IFN-α Monotherapy in Treatment-Naive Individuals with HIV-1 Infection: Evidence of Potent Suppression of Viral Replication Journal of Interferon and Cytokine Research. ,vol. 21, pp. 861- 869 ,(2001) , 10.1089/107999001753238114
Alfredo Alberti, Nathan Clumeck, Simon Collins, Wolfram Gerlich, Jens Lundgren, Giorgio Palù, Peter Reiss, Rodolphe Thiebaut, Ola Weiland, Yazdan Yazdanpanah, Stefan Zeuzem, (The ECC Jury), SHORT STATEMENT OF THE FIRST EUROPEAN CONSENSUS CONFERENCE ON THE TREATMENT OF CHRONIC HEPATITIS B AND C IN HIV CO-INFECTED PATIENTS Journal of Hepatology. ,vol. 42, pp. 615- 624 ,(2005) , 10.1016/J.JHEP.2005.03.003
Raymond T. Chung, Janet Andersen, Paul Volberding, Gregory K. Robbins, Tun Liu, Kenneth E. Sherman, Marion G. Peters, Margaret J. Koziel, Atul K. Bhan, Beverly Alston, Dodi Colquhoun, Tom Nevin, George Harb, Charles van der Horst, Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. The New England Journal of Medicine. ,vol. 351, pp. 451- 459 ,(2004) , 10.1056/NEJMOA032653
Francesca J. Torriani, Maribel Rodriguez-Torres, Jürgen K. Rockstroh, Eduardo Lissen, Juan Gonzalez-García, Adriano Lazzarin, Giampiero Carosi, Joseph Sasadeusz, Christine Katlama, Julio Montaner, Hoel Sette, Sharon Passe, Jean De Pamphilis, Frank Duff, Uschi Marion Schrenk, Douglas T. Dieterich, Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. The New England Journal of Medicine. ,vol. 351, pp. 438- 450 ,(2004) , 10.1056/NEJMOA040842
Scott McCallister, Hernan Valdez, Kevin Curry, Thomas MacGregor, Marie Borin, William Freimuth, Yenyung Wang, Douglas L. Mayers, A 14-day dose-response study of the efficacy, safety, and pharmacokinetics of the nonpeptidic protease inhibitor tipranavir in treatment-naive HIV-1-infected patients. Journal of Acquired Immune Deficiency Syndromes. ,vol. 35, pp. 376- 382 ,(2004) , 10.1097/00126334-200404010-00007
Fabrice Carrat, Firouzé Bani-Sadr, Stanislas Pol, Eric Rosenthal, Françoise Lunel-Fabiani, Asmae Benzekri, Patrice Morand, Cécile Goujard, Gilles Pialoux, Lionel Piroth, Dominique Salmon-Céron, Claude Degott, Patrice Cacoub, Christian Perronne, ANRS HCO2 Ribavic Study Team, None, Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA. ,vol. 292, pp. 2839- 2848 ,(2004) , 10.1001/JAMA.292.23.2839
Francesca J. Torriani, Ruy M. Ribeiro, Tari L. Gilbert, Uschi M. Schrenk, Marietta Clauson, DeeDee M. Pacheco, Alan S. Perelson, Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) dynamics during HCV treatment in HCV/HIV coinfection. The Journal of Infectious Diseases. ,vol. 188, pp. 1498- 1507 ,(2003) , 10.1086/379255
Miro Jm, Gatell Jm, Aznar E, Comparison of ribavirin and placebo in CDC group III human immunodeficiency virus infection. Spanish Ribavirin Trial Group. The Lancet. ,vol. 338, ,(1991)
Lionel Piroth, Stanislas Pol, Cécile Goujard, Dominique Salmon-Céron, Asmae Benzekri, Eric Rosenthal, Fabrice Carrat, Firouzé Bani-Sadr, Françoise Lunel-Fabiani, Gilles Pialoux, Patrice Morand, Pegylated Interferon Alfa-2b vs Standard Interferon Alfa-2b, Plus Ribavirin, for Chronic Hepatitis C in HIV-Infected Patients ,(2017)